Dolasetron

Products

Dolasetron (Anzemet) is no longer on the market in many countries. It had been approved since 1999. The solution for injection was withdrawn in 2011 because of possible adverse effects (prolongation of the QT interval, cardiac arrhythmias), and later the tablets also went off the market.

Structure and properties

Dolasetron (C19H20N2O3, Mr = 324.4 g/mol) is present in the drug as dolasetron mesilate monohydrate.

Effects

Dolasetron (ATC A04AA04) is antiemetic and a sertotonin antagonist at 5-HT3 receptors.

Indication

Prevention of nausea and vomiting during cytotoxic chemotherapy.